Nicotinamide adenine dinucleotide (NAD+) is a pyridine-nucleotide coenzyme that functions both as the central electron carrier of cellular metabolism and as a consumed substrate for signaling enzymes such as sirtuins, PARPs, and CD38. First identified in 1906 as a heat-stable cofactor for yeast fermentation, it has since become one of the most extensively studied molecules in biochemistry and a focal point of aging and metabolism research. This monograph summarizes the published scientific literature on NAD+ (PubChem CID 5892; C21H27N7O14P2) as a research reagent, covering its chemistry, mechanism, and documented laboratory applications. It is presented strictly for laboratory and research use only.

Background & Discovery

Nicotinamide adenine dinucleotide (NAD+) is among the most historically significant molecules in biochemistry. Its discovery traces to 1906, when Arthur Harden and William Young identified a heat-stable, dialyzable "coferment" (originally termed cozymase) that was required for yeast fermentation. Over the following decades the molecule’s structure and function were resolved through the work of Hans von Euler-Chelpin, who characterized cozymase as a nucleotide, and Otto Warburg, who demonstrated that the nicotinamide (vitamin B3-derived) portion of the molecule serves as the hydride-accepting site in biological hydrogen transfer. Arthur Kornberg’s later elucidation of NAD biosynthesis further cemented its central place in intermediary metabolism. Several of these investigations were recognized with Nobel Prizes, underscoring how foundational NAD+ became to the understanding of cellular energetics.

For much of the twentieth century NAD+ was studied primarily as a redox coenzyme: an obligatory electron carrier cycling between its oxidized (NAD+) and reduced (NADH) states across glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation. Interest broadened dramatically at the turn of the millennium when Imai and colleagues reported that the yeast silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase, revealing that NAD+ is not only an electron shuttle but also a consumed substrate for signaling enzymes. This finding reframed NAD+ as a node connecting cellular energy status to gene regulation, DNA repair, and lifespan-related pathways.

Within the research-reagent landscape, NAD+ is categorized as a pyridine-nucleotide coenzyme and biochemical cofactor. It is widely used as a laboratory standard and enzymatic substrate, and it has become a focal point of aging and metabolism research because tissue NAD+ levels are reported to decline with age. This review presents what the peer-reviewed literature reports about NAD+ for laboratory and research use only; it is not intended to guide human use and makes no therapeutic claims.

Chemical Identity

Structure & Physicochemical Properties

Structurally, NAD+ is a dinucleotide composed of two ribonucleotides joined through their 5′-phosphate groups by a pyrophosphate (diphosphate) bridge. One nucleotide contributes an adenine base (as adenosine monophosphate, AMP), while the other contributes a nicotinamide base (as nicotinamide mononucleotide, NMN). The redox-active center is the nicotinamide ring: in the oxidized form the pyridinium nitrogen carries a formal positive charge (hence "NAD+"), and reduction to NADH occurs by formal hydride addition at the C4 position of the ring. Reference databases assign NAD+ the molecular formula C21H27N7O14P2, an average molecular weight of approximately 663.43 g/mol, and the InChIKey BAWFJGJZGIEFAR-NNYOXOHSSA-N (PubChem CID 5892), with the beta-anomeric configuration at the nicotinamide ribose being the biologically relevant stereochemistry.

As a highly polar, charged molecule, NAD+ is freely soluble in water and essentially insoluble in nonpolar organic solvents; the free-acid material is hygroscopic. Published handling literature notes that the oxidized form (NAD+) is comparatively stable in acidic conditions but labile under alkaline conditions, whereas the reduced form (NADH) shows the opposite stability profile. NAD+ absorbs ultraviolet light near 260 nm owing to its adenine chromophore, and reduction to NADH introduces a characteristic additional absorbance band near 340 nm; this 340 nm signal, together with NADH fluorescence, forms the analytical basis of a vast number of coupled enzymatic assays. Both dry powder and reconstituted solutions are sensitive to heat, repeated freeze-thaw, and prolonged exposure to neutral-to-basic aqueous conditions.

Mechanism of Action — as described in the literature

The best-characterized role of NAD+ is as a redox coenzyme. Because the nicotinamide ring reversibly accepts and donates a hydride ion, the NAD+/NADH couple functions as the principal mobile electron carrier of catabolism. Dehydrogenases of glycolysis, the tricarboxylic acid cycle, and fatty-acid oxidation reduce NAD+ to NADH, which then delivers electrons to complex I of the mitochondrial electron transport chain to drive ATP synthesis. A closely related phosphorylated couple, NADP+/NADPH, is maintained in a more reduced state and supports reductive biosynthesis and antioxidant defense, so that the ratios of these pyridine-nucleotide pairs act as readouts of cellular energy and redox status.

Beyond redox cycling, a second and mechanistically distinct role emerged from the finding that NAD+ is a consumed substrate for several enzyme families. Imai and colleagues demonstrated that the sirtuin Sir2 is an NAD-dependent deacetylase, cleaving NAD+ to remove acetyl groups from protein lysines and generating nicotinamide plus 2′-O-acetyl-ADP-ribose in the process. Mammalian sirtuins (SIRT1-7) extend this chemistry to deacetylation, deacylation, and ADP-ribosylation reactions, coupling the abundance of NAD+ to the regulation of transcription factors, metabolic enzymes, and mitochondrial biogenesis. Because these reactions physically consume the coenzyme, sirtuin activity is intrinsically sensitive to the size of the cellular NAD+ pool.

Two further NAD+-consuming systems compete for the same pool. Poly(ADP-ribose) polymerases (PARPs), activated notably by DNA strand breaks, cleave NAD+ to build poly(ADP-ribose) chains on target proteins during the DNA-damage response, and extensive PARP activation can substantially deplete NAD+. The ecto-glycohydrolases CD38 and CD157 hydrolyze NAD+ (and precursors such as NMN) to generate calcium-mobilizing second messengers including cyclic ADP-ribose. Camacho-Pereira and colleagues reported that CD38 expression rises with age and, through a SIRT3-dependent mechanism, drives NAD+ decline and mitochondrial dysfunction, positioning CD38 as a major consumer that constrains NAD+ availability to sirtuins and PARPs.

Cellular NAD+ levels are set by the balance between this consumption and biosynthesis. Mammalian cells generate NAD+ de novo from tryptophan via the kynurenine pathway, through the Preiss-Handler pathway from nicotinic acid, and, quantitatively most important, through a salvage pathway in which nicotinamide is recycled by nicotinamide phosphoribosyltransferase (NAMPT) to NMN and then converted to NAD+ by NMN adenylyltransferases (NMNATs). The dietary precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) feed this salvage route, which is why they are so frequently used experimentally to raise intracellular NAD+. NAD+ is also compartmentalized among the cytosol, mitochondria, and nucleus, and reviews by Canto, Katsyuba, and Covarrubias and their colleagues emphasize that this subcellular organization shapes how energy metabolism and NAD+-dependent signaling are coordinated.

Finally, the literature links falling NAD+ to cellular aging phenotypes. Gomes and colleagues reported that a decline in nuclear NAD+ during aging reduces SIRT1 activity, leading to stabilization of HIF-1alpha and a "pseudohypoxic" state that disrupts nuclear-mitochondrial communication and lowers the expression of mitochondrially encoded respiratory proteins; restoring NAD+ reversed these changes in their model. Covarrubias and colleagues subsequently connected age-related tissue NAD+ decline to accumulation of senescent cells that activate CD38-expressing macrophages. Together these strands frame NAD+ as an integrator of redox chemistry, protein signaling, DNA repair, and aging biology.

Key Published Findings

• Sirtuin biochemistry (foundational mechanism): In yeast and in vitro biochemical systems, researchers demonstrated that the silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase, establishing that NAD+ acts as a consumed co-substrate for the sirtuin enzyme family rather than solely as a redox carrier.[2]
• Aging and mitochondrial communication (in vivo mouse): In aged mice, investigators reported that declining nuclear NAD+ reduced SIRT1 activity and stabilized HIF-1alpha, producing a pseudohypoxic state that impaired nuclear-mitochondrial communication and lowered mitochondrially encoded OXPHOS subunits; raising NAD+ reversed several of these changes in their model.[1]
• NAD+-consuming enzymes and aging (mouse / cell): Researchers observed that the NADase CD38 increases with age and, through a SIRT3-dependent mechanism, drives age-related NAD+ decline and mitochondrial dysfunction, with CD38-knockout mice showing protection from NAD+ loss.[5]
• Preclinical metabolic phenotyping (mouse): In a 12-month study of orally administered NMN (an NAD+ precursor) in mice, researchers reported suppression of age-associated body-weight gain, enhanced energy metabolism and physical activity, and improved insulin sensitivity without observed toxicity.[4]
• Human clinical pharmacology (NAD+ precursor): In a randomized, placebo-controlled crossover trial in healthy middle-aged and older adults, oral nicotinamide riboside was reported to be well tolerated and to raise blood NAD+ metabolism, which the authors characterized as evidence that a precursor can elevate systemic NAD+ in humans.[7]
• Human metabolic study (NAD+ precursor): In a randomized, placebo-controlled trial in prediabetic postmenopausal women, researchers reported that oral NMN increased skeletal-muscle insulin sensitivity and muscle insulin signaling markers over the study period.[11]
• Senescence and tissue NAD+ decline (mouse): Investigators reported that senescent cells accumulating in tissues during aging promote NAD+ decline by activating CD38-expressing pro-inflammatory macrophages, linking cellular senescence to systemic NAD+ metabolism.[8]

Research Applications

• Used as a standard redox cofactor and enzymatic substrate in coupled dehydrogenase assays that monitor NADH formation at 340 nm
• Investigated as the obligate co-substrate in in vitro sirtuin (SIRT1-7) deacetylase and ADP-ribosyltransferase activity assays
• Employed in studies of PARP-mediated poly(ADP-ribosylation) and the DNA-damage response
• Applied in research on CD38/CD157 glycohydrolase activity and cyclic ADP-ribose calcium signaling
• Examined in rodent and cell-based models of aging, cellular senescence, and mitochondrial dysfunction to study NAD+ decline
• Used in metabolic-disease research models (insulin resistance, obesity, energy homeostasis) alongside NAD+ precursors such as NR and NMN
• Investigated in models of neurodegeneration and axonal degeneration where NAD+ metabolism and the SARM1 pathway are implicated
• Utilized as an analytical calibrant and internal reference in LC-MS/MS and enzymatic-cycling assays that quantify cellular NAD+/NADH pools

Related & Comparator Compounds

The most immediate comparator to NAD+ is its own reduced partner, NADH, together forming the redox couple that the literature treats as a single interconverting system; the phosphorylated analogs NADP+ and NADPH constitute a parallel couple that is kept more reduced and is dedicated largely to biosynthetic and antioxidant chemistry rather than catabolic electron transfer. Distinct from these coenzyme forms are the NAD+ biosynthetic precursors: nicotinamide (NAM), nicotinic acid (niacin, NA), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). Published work distinguishes precursors from NAD+ itself on practical grounds: intact NAD+ is a large, charged dinucleotide that does not readily cross cell membranes, so experiments aiming to raise intracellular NAD+ frequently use the smaller precursors (NR, NMN), which feed the NAMPT-dependent salvage pathway. Much of the animal and human pharmacology literature cited here (Mills, Martens, Yoshino, Rajman and colleagues) accordingly examines NR and NMN as tools to modulate the NAD+ pool, whereas NAD+ itself is more commonly used as a defined biochemical reagent and enzymatic substrate in vitro.

Handling, Reconstitution & Storage

In a research setting, NAD+ (free acid) is typically supplied as a lyophilized or crystalline hygroscopic powder and is commonly described as being stored desiccated at -20 C (or colder for long-term storage), protected from moisture and light. Published handling notes indicate that the powder should be equilibrated to room temperature before opening to minimize condensation, and reconstituted in water or an appropriate cold buffer; because NAD+ is labile under alkaline conditions, mildly acidic to neutral buffers are generally favored, and freshly prepared solutions are preferred. Working stocks are usually aliquoted to avoid repeated freeze-thaw cycles, kept cold during use, and not held for extended periods at neutral-to-basic pH or elevated temperature. These practices reflect the compound’s hygroscopicity and pH-dependent stability and are described strictly for laboratory research handling, not for human use.

Analytical & Quality Considerations

Analytical characterization of research-grade NAD+ typically combines chromatographic purity assessment with orthogonal identity confirmation. Reversed-phase or ion-pair HPLC (with UV detection near 260 nm) is widely used to quantify purity and to resolve NAD+ from related species such as NADH, NADP+, nicotinamide, and ADP-ribose degradation products, while high-resolution LC-MS/MS confirms identity against the expected monoisotopic mass (approximately 663.11 Da for C21H27N7O14P2) and fragmentation pattern. Enzymatic cycling assays and the diagnostic 340 nm absorbance/fluorescence of enzymatically generated NADH provide functional confirmation that the material behaves as an authentic coenzyme, and NMR can verify the beta-anomeric configuration and structural integrity. Because purity, water content (the material is hygroscopic), counter-ion identity, and degradation products directly affect enzymatic assay results, an independent third-party certificate of analysis reporting HPLC purity, identity (MS/NMR), and residual moisture is important for reproducible research and for distinguishing genuine NAD+ from partially degraded or precursor-contaminated lots.

Frequently Asked Research Questions

Q. What is NAD+ and how does it differ from NADH?
A. NAD+ (beta-nicotinamide adenine dinucleotide) is the oxidized form of a pyridine-nucleotide coenzyme; NADH is its reduced form. The two interconvert as the nicotinamide ring accepts or donates a hydride, and together they serve as the principal electron-carrying couple of catabolic metabolism. NAD+ additionally acts as a consumed substrate for sirtuins, PARPs, and CD38/CD157, whereas NADH functions mainly in redox electron transfer.

Q. What is the confirmed molecular formula, weight, and CAS number of NAD+?
A. Authoritative databases (PubChem CID 5892) list the molecular formula as C21H27N7O14P2, an average molecular weight of about 663.43 g/mol, a monoisotopic mass near 663.11 Da, and CAS number 53-84-9 for the free-acid oxidized form. The InChIKey is BAWFJGJZGIEFAR-NNYOXOHSSA-N.

Q. Why is NAD+ studied in aging and metabolism research?
A. Peer-reviewed studies report that tissue NAD+ levels decline with age and that this decline is associated with reduced sirtuin activity, mitochondrial dysfunction, and increased NAD+ consumption by enzymes such as CD38. Because NAD+ sits at the intersection of energy metabolism, DNA repair, and cellular signaling, researchers use it and its precursors as tools to probe these aging- and metabolism-related pathways in cell and animal models.

Q. How do NAD+ precursors like NR and NMN relate to NAD+ itself?
A. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are biosynthetic precursors that feed the NAMPT-dependent salvage pathway to generate NAD+. Because intact NAD+ is a large, charged molecule with limited cell-membrane permeability, much of the published animal and human research uses these smaller precursors to raise intracellular NAD+, while NAD+ itself is often used directly as a defined enzymatic substrate in vitro.

Q. How is NAD+ handled and stored in a laboratory setting?
A. Research literature describes NAD+ free acid as a hygroscopic powder stored desiccated at -20 C or colder, protected from moisture and light. It is reconstituted in water or a cold neutral-to-mildly-acidic buffer (it is labile under alkaline conditions), aliquoted to avoid freeze-thaw cycles, and used fresh. These are research-handling notes only and do not constitute guidance for human use.

Q. How is the identity and purity of research-grade NAD+ verified?
A. Typical quality control combines HPLC purity analysis (UV detection near 260 nm) with LC-MS/MS identity confirmation against the expected mass, plus enzymatic/UV functional checks using the 340 nm NADH signal and, where needed, NMR. An independent third-party certificate of analysis reporting purity, identity, and residual moisture helps ensure reproducible results and rule out degradation or precursor contamination.

Peer-Reviewed References

1. Gomes AP, Price NL, Ling AJY, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013. PubMed →
2. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000. PubMed →
3. Canto C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metabolism. 2015. PubMed →
4. Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS, Uchida K, Yoshino J, Imai SI. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metabolism. 2016. PubMed →
5. Camacho-Pereira J, Tarrago MG, Chini CCS, Nin V, Escande C, Warner GM, Puranik AS, Schoon RA, Reid JM, Galina A, Chini EN. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism. 2016. PubMed →
6. Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism. 2018. PubMed →
7. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018. PubMed →
8. Covarrubias AJ, Kale A, Perrone R, Lopez-Dominguez JA, Pisco AO, Kasler HG, Schmidt MS, Heckenbach I, et al. (Campisi J, Verdin E). Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nature Metabolism. 2020. PubMed →
9. Katsyuba E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nature Metabolism. 2020. PubMed →
10. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021. PubMed →
11. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PubMed →

For laboratory and research use only. Not for human or veterinary use, diagnosis, or treatment. This overview summarizes published scientific literature for informational and educational purposes and is not medical advice; no claims are made regarding safety or efficacy in humans.

← Back to the Research Library · View NAD+ → · COA & Testing